We are delighted to be holding the seventh annual lecture for Professor Peter Noyce CBE on Monday 18 December 2023 at 3.30pm and we would like to invite you to join us at this important event.
Professor Dyfrig Hughes, Bangor University, has kindly agreed to deliver the lecture this year entitled . ‘Medicines optimisation research: Developing the evidence and informing policy and practice’.
The lecture will be held in Lecture theatre 5 in the Stopford Building, University of Manchester and remotely via Zoom.
If you would like to attend, could you please register by completing this online form
Abstract:
Medicines are the second highest cost to the NHS after staff. There is significant potential, therefore, for inappropriate prescribing or for sub-optimal use of medicines to impose a large opportunity cost. Medicines optimisation is about achieving effective, safe and cost-effective use of medicines in order to improve health outcomes. This involves, amongst other interventions and approaches: personalising therapy, reducing inappropriate polypharmacy, improving medication adherence, and prioritising high-value medicines. This lecture reflects on over 25 years of research focusing on the economics of medicines, pharmacogenetic tests, medication adherence and in developing pharmaceutical policies aimed ultimately to maximise population health.
Biography: Professor Dyfrig Hughes
Dyfrig Hughes is Professor of Pharmacoeconomics at the North Wales Medical School, Bangor University where he is also co-director of the Centre for Health Economics and Medicines Evaluation and Director for Research, Impact and Engagement. Coming from a background in pharmacy and pharmacology, Dyfrig's research focuses primarily on pharmaceutical economics, policy and prescribing. He has led and contributed to research totalling £90m in value, resulting in over 240 publications.
Dyfrig has national roles supporting the NHS, including being vice-chair of the All Wales Medicines Strategy Group, chair of the National Pharmacogenomics Group (for Wales), and chair of the Pharmacogenomics Test Evaluation Working Group (NHSE). He is also member of the NHSE Genomics Informed Medicines Optimisation Group, and has advisory roles relating to the MHRA’s Yellow Card Biobank project, and the EMA’s Committee for Orphan Medicinal Products. Dyfrig has been a Health and Care Research Wales Senior Research Leader since 2016, and was inaugural president of the International Society for Medication Adherence. He is also honorary professor at the Department of Pharmacology and Therapeutics, University of Liverpool, and visiting professor at the Faculty of Pharmacy, University of Turin.
